Cargando…
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI)...
Autores principales: | Mancini, Manuela, De Santis, Sara, Monaldi, Cecilia, Castagnetti, Fausto, Lonetti, Annalisa, Bruno, Samantha, Dan, Elisa, Sinigaglia, Barbara, Rosti, Gianantonio, Cavo, Michele, Gugliotta, Gabriele, Soverini, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391055/ https://www.ncbi.nlm.nih.gov/pubmed/35992847 http://dx.doi.org/10.3389/fonc.2022.901132 |
Ejemplares similares
-
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019) -
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022) -
Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019) -
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
por: Soverini, Simona, et al.
Publicado: (2016) -
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe
por: Li, Jingjing, et al.
Publicado: (2015)